|Dr. Pavan Cheruvu M.D.||CEO & Director||733.62k||N/A||1982|
|Mr. David W. Nassif||CFO & Gen. Counsel||656.25k||N/A||1954|
|Dr. Gavin Corcoran FACP, M.D.||Chief R&D Officer of Axovant Sciences, Inc.||579.71k||N/A||1963|
|Dr. Parag V. Meswani Pharm.D.||Chief Commercial Officer||N/A||N/A||N/A|
|Dr. Guangping Gao||Chief AAV Scientific Advisor||N/A||N/A||N/A|
Sio Gene Therapies, Inc., a clinical-stage gene therapy company, focuses on developing various product candidates for debilitating neurodegenerative diseases. The company's clinical-stage programs include AXO-Lenti-PD program for the treatment of Parkinson's disease; AXO-AAV-GM1 program for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2 program for the treatment of GM2 gangliosidosis. It has a license agreement with Oxford BioMedica (UK) Ltd. and The University of Massachusetts Medical School. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was founded in 2014 and is based in New York, New York.
Sio Gene Therapies, Inc.’s ISS Governance QualityScore as of December 2, 2020 is 9. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 1; Compensation: 10.